Long-term survival of a patient with pulmonary metastatic urothelial carcinoma following metastasectomy

Cisplatin-based systemic chemotherapy is the gold standard for the treatment of patients with metastatic urothelial carcinoma (UC), which is a chemosensitive cancer. However, long-term survival has been deemed disappointing. We describe here a case of UC with solitary pulmonary metastasis who had su...

Full description

Bibliographic Details
Main Authors: Kenichi Hasebe, Taku Naiki, Risa Oda, Toshiki Etani, Keitaro Iida, Yosuke Sugiyama, Satoshi Nozaki, Ryosuke Ando, Noriyasu Kawai, Ryoichi Nakanishi, Takahiro Yasui
Format: Article
Language:English
Published: Elsevier 2018-11-01
Series:Urology Case Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2214442018302845
Description
Summary:Cisplatin-based systemic chemotherapy is the gold standard for the treatment of patients with metastatic urothelial carcinoma (UC), which is a chemosensitive cancer. However, long-term survival has been deemed disappointing. We describe here a case of UC with solitary pulmonary metastasis who had successfully achieved long-term disease-free survival by combination of cisplatin-based chemotherapy and pulmonary metastasectomy. From the finding of this article, we propose that adjuvant chemotherapy may be considered as a viable option after metastasectomy in low volume pulmonary metastatic UC patients. Keywords: Urothelial carcinoma, Pulmonary metastasis, Bladder, Metastasectomy
ISSN:2214-4420